Linezolid (Zyvox) is a new agent for the treatment of MRSA (methicillin-resistant Staphylococcus aureus) and VRE (vancomycin-resistant enterococci).
How can healthcare professionals (all healthcare workers, not just nurses, CNA, and physicians) ensure that this medication doesn’t become ineffective as bacteria become resistant to the agent?
What are the implications of bacteria that continue to mutate as a means of surviving current antimicrobial therapy